Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karlsson, J.
Right arrow Articles by Påhlman, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karlsson, J.
Right arrow Articles by Påhlman, S.
Clinical Cancer Research Vol. 10, 3179-3188, May 1, 2004
© 2004 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Arsenic Trioxide-Induced Death of Neuroblastoma Cells Involves Activation of Bax and Does Not Require p53

Jenny Karlsson1, Ingrid Øra1,3, Isabella Pörn-Ares2 and Sven Påhlman1

1 Divisions of Molecular Medicine and 2 Experimental Pathology, Departments of Laboratory Medicine, Malmö, and 3 Pediatrics, Oncology-Hematology Section, Lund University Hospital, Lund, Sweden

Purpose: On the basis of clinical studies showing that arsenic trioxide (As2O3), via an apoptotic mechanism, and with minimal toxicity induces complete remission in patients with refractory acute promyelocytic leukemia and that multidrug-resistant and p53-mutated neuroblastoma cells are sensitive to As2O3 both in vitro and in vivo, we searched for molecular mechanisms involved in the As2O3-induced neuroblastoma cell death.

Experimental Design: We have studied the effect of As2O3 on the expression and cellular localization of proteins involved in drug-induced death in two neuroblastoma cell lines with intact p53 and two with mutated p53, the latter two displaying multidrug resistance.

Results: As2O3 provoked Bax expression in all tested neuroblastoma cell lines, including SK-N-BE(2) cells with mutated p53 and LA-N-1 cells, which have a deleted p53. In all cell lines exposed to As2O3, p21 Bax was proteolytically cleaved in a calpain-dependent way into the more proapoptotic p18 Bax, which was detected exclusively in a mitochondria-enriched subcellular fraction. As2O3 also caused an increase of cytoplasmic cytochrome c, translocation of antiapoptosis-inducing factor to the nuclei, and a slight activation of caspase 3. However, inhibition of caspase 3 did not prevent cell death, whereas inhibition of Bax cleavage was associated with a decreased As2O3-induced cell death.

Conclusions: We show that multidrug-resistant neuroblastoma cells die after exposure to As2O3, independent of functional p53, suggesting activation of a cytotoxic pathway different from that induced by conventional chemotherapeutic agents. We further propose that proteolytic activation of Bax is an important event in As2O3-induced cell death.




This article has been cited by other articles:


Home page
J. Cell Biol.Home page
F. Demarchi, C. Bertoli, T. Copetti, I. Tanida, C. Brancolini, E.-L. Eskelinen, and C. Schneider
Calpain is required for macroautophagy in mammalian cells
J. Cell Biol., November 20, 2006; 175(4): 595 - 605.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
R. Thierbach, T. J. Schulz, F. Isken, A. Voigt, B. Mietzner, G. Drewes, J.-C. von Kleist-Retzow, R. J. Wiesner, M. A. Magnuson, H. Puccio, et al.
Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice
Hum. Mol. Genet., December 15, 2005; 14(24): 3857 - 3864.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. Karlsson, A. Edsjo, S. Pahlman, and H. M. Pettersson
Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia
Mol. Cancer Ther., July 1, 2005; 4(7): 1128 - 1135.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. Lindskog, C. Spenger, J. Jarvet, A. Graslund, and P. Kogner
Predicting Resistance or Response to Chemotherapy by Proton Magnetic Resonance Spectroscopy in Neuroblastoma
J Natl Cancer Inst, October 6, 2004; 96(19): 1457 - 1466.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.